Mankind Pharma IPO will open for subscription on April 25 and close on April 27. Stock will be listed on exchanges on May 9.
The company has set the price band for its IPO at Rs 1,026-1,080 per share, valuing the company at Rs 43,264 crore at the top end of the band. It will raise as much as Rs 4,326.36 crore at the upper band of the price range.
IPO consists of a pure offer for sale of upto 40.06 million shares by its existing shareholders and promoters.
Mankind Pharma has a strong focus on the domestic market. 97.60% of its total revenue in the FY22 is from India. Sales from class II-IV cities and rural areas contributed 47 percent to Mankind Pharma’s domestic sales.
Mankind Pharma used to be the market leader in domestic prescription medicine for long, only to be toppled by Sun Pharma last year. The company has developed 36 brands in the pharmaceutical business and boasts one of the largest networks of medical representatives in the Indian pharmaceutical market.
Apart from its popular Manforce Condoms, Prega News, and Unwanted-72 brands, Mankind Pharma has also established a range of consumer healthcare brands in categories such as antacid powders (Gas-O-Fast), vitamin and mineral supplements (Health OK brand), and anti-acne preparations (AcneStar brand), among others.
Mankind’s consumer healthcare segment makes for 9% of its topline.
Return on net worth (RoNW) for Mankind stood at 23.29 percent in FY22.
| Subscribe To Our Free Newsletter |
